{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:29:50Z","timestamp":1792621790275,"version":"4.5.0"},"reference-count":29,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Major depressive disorder (MDD) is one of the most common psychiatric disorders. Recent studies have shown a strong association between MDD and peripheral inflammation, shown by a higher incidence of depression in patients with inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus. Dermatomyositis (DM), an idiopathic inflammatory connective tissue disease that is associated with inflammation, predominantly affects the skin and skeletal muscle. The association between DM and MDD in the context of inflammation has seldom been reported. Here we report a 30- year- old Caucasian female with symptoms of depression dating back to 2 years. These symptoms started after cutaneous manifestations of DM. In the past two years, her DM symptoms have worsened that paralleled an increase of depressive symptoms. Also, during the course of the patient\u2019s DM, we tracked elevated inflammatory markers including creatine kinase and aldolase, whereas C-reactive protein, C3, and C4 were in a high normal range which correlated with worsening of depression. Hence, a temporal relationship between the onset of MDD and DM symptoms suggests that inflammation may be a common mechanism linking these two conditions.<\/jats:p>","DOI":"10.64719\/pb.4569","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"22-28","source":"Crossref","is-referenced-by-count":5,"title":["Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation"],"prefix":"10.64719","volume":"48","author":[{"given":"Abhishek","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badari","family":"Birur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Money KM, Olah Z, Korade Z, Garbett KA, Shelton RC, Mirnics K. An altered peripheral IL6 response in major depressive disorder. Neurobiology of disease. 2016;89:46\u201354.","DOI":"10.1016\/j.nbd.2016.01.015"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62(6):593\u2013602.","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851\u2013858.","DOI":"10.1016\/S0140-6736(07)61415-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Dahl J, Ormstad H, Aass HC et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014;45:77\u201386.","DOI":"10.1016\/j.psyneuen.2014.03.019"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446\u2013457.","DOI":"10.1016\/j.biopsych.2009.09.033"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Erdem M, Celik C, Cayci T et al. Serum haptoglobin levels in patients with melancholic and nonmelancholic major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2011;35(4):944\u2013947.","DOI":"10.1016\/j.pnpbp.2011.01.009"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Maes M, Scharpe S, Meltzer HY et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Research. 1993;49(1):11\u201327.","DOI":"10.1016\/0165-1781(93)90027-E"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9(11):853\u2013858.","DOI":"10.1006\/cyto.1997.0238"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology. 2006;27(1):24\u201331.","DOI":"10.1016\/j.it.2005.11.006"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Setiawan E, Wilson AA, Mizrahi R et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72(3):268\u2013275.","DOI":"10.1001\/jamapsychiatry.2014.2427"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine. 2009;71(2):171\u2013186.","DOI":"10.1097\/PSY.0b013e3181907c1b"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yirmiya R, Pollak Y, Morag M et al. Illness, cytokines, and depression. Annals of the New York Academy of Sciences. 2000;917:478\u2013487.","DOI":"10.1111\/j.1749-6632.2000.tb05412.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord. 2009;119(1-3):181\u2013185.","DOI":"10.1016\/j.jad.2009.02.017"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961\u2013966.","DOI":"10.1056\/NEJM200103293441303"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kraus MR, Schafer A, Schottker K et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008;57(4):531\u2013536.","DOI":"10.1136\/gut.2007.131607"},{"key":"ref16","unstructured":"Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression\u2019s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinology letters. 2011;32(1):7\u201324."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Achtman J, Kling MA, Feng R, Okawa J, Werth VP. A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. Journal of the American Academy of Dermatology. 2016;74(2):377\u2013379.","DOI":"10.1016\/j.jaad.2015.09.016"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosomatic Medicine. 2002;64(1):52\u201360.","DOI":"10.1097\/00006842-200201000-00008"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflammatory Bowel Diseases. 2009;15(7):1105\u20131118.","DOI":"10.1002\/ibd.20873"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lo Fermo S, Barone R, Patti F et al. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(6):742\u2013748.","DOI":"10.1177\/1352458510365157"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kekow J, Moots RJ, Emery P et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010;69(1):222\u2013225.","DOI":"10.1136\/ard.2008.102509"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29\u201335.","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dauden E, Griffiths C, Ortonne JP et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23:1374\u20131382.","DOI":"10.1111\/j.1468-3083.2009.03321.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Raison Cl RREWBJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. Archives of General Psychiatry. 2012;1:11.","DOI":"10.1001\/2013.jamapsychiatry.4"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine. 1977;56(4):255\u2013286.","DOI":"10.1097\/00005792-197707000-00001"},{"key":"ref26","unstructured":"Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. The Journal of Rheumatology. 1985;12(6):1140\u20131148."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971\u2013982.","DOI":"10.1016\/S0140-6736(03)14368-1"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Sawhney S, Murray KJ. Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology (Oxford, England) 2001;40(11):1293\u20131298.","DOI":"10.1093\/rheumatology\/40.11.1293"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Goreshi R, Chock M, Foering K et al. Quality of life in dermatomyositis. Journal of the American Academy of Dermatology. 2011;65(6):1107\u20131116.","DOI":"10.1016\/j.jaad.2010.10.016"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:34:28Z","timestamp":1791315268000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/major-depressive-disorder-following-dermatomyositis-a-case-linking-depression-with-inflammation\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4569","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}